Reported 2026-03-21Lot TB15-01092026-199.51% purity · 16.10 mg
Open COA
Lyophilized Peptides
TB-500 (Thymosin Beta-4)
Literature identity: thymosin β4 residues 17–23; Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH
A seven-residue acetylated peptide corresponding to residues 17–23 of thymosin β4; it is not the full-length thymosin β4 peptide.
CatalogTB-PW
ManufacturerRemetide
PurityTarget ≥99% by RP-HPLC; lot result controls
PackResearch pack · supplied amount shown on product record
Price range: $65.00 through $98.00 Current catalog price; lot availability controls fulfillment.
AvailabilityIn stock
For laboratory research use only. Not for human or veterinary use.
TB-500 (Thymosin Beta-4)$65.00 – $98.00Price range: $65.00 through $98.00
01Lot documentationCOA and analytical-record model
02Defined specificationMethod and result remain lot specific
03Tracked fulfillmentShipping method and lot allocation confirmed at order review
04Responsible useNon-clinical laboratory context
Lot documentation
Current Certificate of Analysis
13 approved certificates are attached to this product record.
Reported 2026-02-24Lot TB1012222025-J99.82% purity · 11.99 mg
Open COA
Reported 2026-02-07Lot TB 500-02032026-J99.488% purity · 55.54 mg
Open COA
Reported 2026-02-05Lot TB10122230225-J99.335% purity · 10.19 mg
Open COA
Reported 2026-01-31Lot TB10-012320626-1299.53% purity · 12.43 mg
Open COA
Reported 2026-01-13Lot TB15-0109026-J99.178% purity · 18.26 mg
Open COA
Reported 2025-12-24Lot TB10-12220025-J99.721% purity · 11.49 mg
Open COA
Reported 2025-12-11Lot TB-50099.624% purity · 11.43 mg
Open COA
Reported 2025-09-25Lot TB1009232025-J99.375% purity · 10.39 mg
Open COA
Reported 2025-08-13Lot 253030198.77% purity · 4.44 mg
Open COA
Reported 2025-08-05Lot TB41007032025-1099.5% purity · 10.76 mg
Open COA
Reported 2025-06-19Lot TB410061620250-0399.74% purity · 10.32 mg
Open COA
Reported 2025-05-02Lot TB410042120250199.9% purity
Open COA
Technical information
Chemical & material record
Presented in a scientific-catalog format so the material can be evaluated by identity, form and documentation before purchase.
- Identity
- TB-500 research peptide; salt form controlled by the approved specification
- Synonyms
- Literature identity: thymosin β4 residues 17–23; Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH
- CAS number
- See approved Remetide material specification
- Molecular formula
- See approved Remetide material specification
- Formula weight
- See approved Remetide material specification
- Sequence / identity note
- Literature identity: Ac-LKKTETQ-OH; production identity must match the approved lot record
- Manufacturer
- Remetide
- Manufacturing role
- Custom peptide synthesis and manufacture
- Form
- Lyophilized, non-sterile research material
- Purity specification
- Target ≥99% by RP-HPLC; lot result controls
- Storage
- -20°C, dry and protected from light; follow lot documentation
- Pack size
- Research pack · supplied amount shown on product record
- Catalog number
- TB-PW
Research context
Published research & product context
Published literature is presented separately from lot-specific identity, purity and analytical results.
TB-500 is an acetylated heptapeptide corresponding to amino-acid residues 17–23 of thymosin β4, an actin-sequestering peptide. Distinguishing this fragment from full-length thymosin β4 is essential for identity, formula, mass and literature interpretation.
Published research reported inhibition of PDGF-BB-stimulated hepatic stellate-cell proliferation and migration at 10 ng/mL. A separate mouse study evaluated topical TB-500 in a skin-wound model. These are experimental observations and are not administration guidance.
Selected published findings
- Corresponds to the actin-binding-domain region of thymosin β4.
- Inhibited PDGF-BB-stimulated hepatic stellate-cell proliferation and migration in a published cellular study.
- Was evaluated in a non-clinical mouse skin-wound model.
References and product citations 2
- Shah, R., Reyes-Gordillo, K., and Rojkind, M. Thymosin β4 inhibits PDGF-BB-induced activation, proliferation, and migration of human hepatic stellate cells via its actin-binding domain. Expert Opinion on Biological Therapy 18(sup1), 177–184 (2018).
- Huang, C.M., Wang, C.C., Barnes, S., et al. In vivo detection of secreted proteins from wounded skin using capillary ultrafiltration probes and mass-spectrometric proteomics. Proteomics 6(21), 5805–5814 (2006).
Literature interpretation: This summary describes published experimental literature and is not a lot specification, clinical claim, use instruction or representation that the supplied research material will reproduce a published result. This record intentionally excludes dosing, administration, clinical outcomes, patient eligibility and therapeutic comparisons.
Intended laboratory context
Illustrative applications
- Analytical comparison
- Method development
- In-vitro laboratory investigation
- Protocol development
Documentation package
Documentation
- PDFCertificate of AnalysisSample
- PDFHPLC chromatogramSample
- PDFMass-spectrometry summarySample
- PDFHandling statementSample
For laboratory research workflows only. Not for administration to humans or animals and not supplied with dosing or reconstitution guidance.
Need a current record?
Documentation before decision-making.
Reference TB-PW and the applicable lot when contacting technical support. Published files support evaluation but do not replace the approved lot COA or material specification.
View documentation model